title: Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently?
authors.forename: Michael L
authors.initials: ML
authors.lastname: Friedlander
authors.forename: Martin Richard
authors.initials: MR
authors.lastname: Stockler
authors.forename: Phyllis
authors.initials: P
authors.lastname: Butow
authors.forename: Madeleine Trudy
authors.initials: MT
authors.lastname: King
authors.forename: Jessica
authors.initials: J
authors.lastname: McAlpine
authors.forename: Anna
authors.initials: A
authors.lastname: Tinker
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: Ledermann
mesh_terms: D004317:Doxorubicin / Q000031:analogs & derivatives*; D034261:Epothilones / Q000627:therapeutic use*; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000627:therapeutic use*
chemical_list: D034261:Epothilones; D011092:Polyethylene Glycols; D004317:Doxorubicin